Phase II study of erlotinib in patients with advanced biliary cancer

Philip A. Philip, Michelle R. Mahoney, Cristine Allmer, James Thomas, Henry Clement Pitot, George Kim, Ross C. Donehower, Tom Fitch, Joel Picus, Charles Erlichman

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Purpose: Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods: Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results: Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion: Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.

Original languageEnglish (US)
Pages (from-to)3069-3074
Number of pages6
JournalJournal of Clinical Oncology
Volume24
Issue number19
DOIs
StatePublished - Jul 1 2006

Fingerprint

Biliary Tract Neoplasms
Exanthema
Epidermal Growth Factor Receptor
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., ... Erlichman, C. (2006). Phase II study of erlotinib in patients with advanced biliary cancer. Journal of Clinical Oncology, 24(19), 3069-3074. https://doi.org/10.1200/JCO.2005.05.3579

Phase II study of erlotinib in patients with advanced biliary cancer. / Philip, Philip A.; Mahoney, Michelle R.; Allmer, Cristine; Thomas, James; Pitot, Henry Clement; Kim, George; Donehower, Ross C.; Fitch, Tom; Picus, Joel; Erlichman, Charles.

In: Journal of Clinical Oncology, Vol. 24, No. 19, 01.07.2006, p. 3069-3074.

Research output: Contribution to journalArticle

Philip, PA, Mahoney, MR, Allmer, C, Thomas, J, Pitot, HC, Kim, G, Donehower, RC, Fitch, T, Picus, J & Erlichman, C 2006, 'Phase II study of erlotinib in patients with advanced biliary cancer', Journal of Clinical Oncology, vol. 24, no. 19, pp. 3069-3074. https://doi.org/10.1200/JCO.2005.05.3579
Philip, Philip A. ; Mahoney, Michelle R. ; Allmer, Cristine ; Thomas, James ; Pitot, Henry Clement ; Kim, George ; Donehower, Ross C. ; Fitch, Tom ; Picus, Joel ; Erlichman, Charles. / Phase II study of erlotinib in patients with advanced biliary cancer. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 19. pp. 3069-3074.
@article{e1a2e1cec1924c3aaac8b0120984cc33,
title = "Phase II study of erlotinib in patients with advanced biliary cancer",
abstract = "Purpose: Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods: Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results: Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81{\%}) of the 36 assessable patients. Seven of the patients (17{\%}; 95{\%} CI, 7{\%} to 31{\%}) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7{\%}) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion: Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.",
author = "Philip, {Philip A.} and Mahoney, {Michelle R.} and Cristine Allmer and James Thomas and Pitot, {Henry Clement} and George Kim and Donehower, {Ross C.} and Tom Fitch and Joel Picus and Charles Erlichman",
year = "2006",
month = "7",
day = "1",
doi = "10.1200/JCO.2005.05.3579",
language = "English (US)",
volume = "24",
pages = "3069--3074",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Phase II study of erlotinib in patients with advanced biliary cancer

AU - Philip, Philip A.

AU - Mahoney, Michelle R.

AU - Allmer, Cristine

AU - Thomas, James

AU - Pitot, Henry Clement

AU - Kim, George

AU - Donehower, Ross C.

AU - Fitch, Tom

AU - Picus, Joel

AU - Erlichman, Charles

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods: Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results: Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion: Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.

AB - Purpose: Epidermal growth factor receptor/human epidermal growth factor receptor 1 and ligand expression is common in biliary cancers (BILI) and may be associated with worse outcome. The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months. Methods: Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was administered continuously at a dose of 150 mg per day orally. Results: Forty-two patients with BILI were enrolled. The median age was 67 years (range, 33 to 82 years). Fifty-two percent of patients had Eastern Cooperative Oncology Group performance status of 1. Fifty-seven percent of patients had received prior chemotherapy for advanced BILI. HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients. Seven of the patients (17%; 95% CI, 7% to 31%) were progression free at 6 months. Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively. All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGFR expression. Three patients (7%) had toxicity-related dose reductions of erlotinib due to grade 2/3 skin rash. Conclusion: Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with biliary cancer. Additional studies with erlotinib as a single agent and in combination with other targeted agents are warranted in this disease.

UR - http://www.scopus.com/inward/record.url?scp=33745970752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745970752&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.05.3579

DO - 10.1200/JCO.2005.05.3579

M3 - Article

VL - 24

SP - 3069

EP - 3074

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -